US 12,168,044 B2
Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers
Toni Weinschenk, Tuebingen (DE); Oliver Schoor, Tuebingen (DE); and Andrea Mahr, Tuebingen (DE)
Assigned to Immatics Biotechnologies GmbH, Tübingen (DE)
Filed by Immatics Biotechnologies GmbH, Tuebingen (DE)
Filed on Oct. 19, 2023, as Appl. No. 18/490,581.
Application 18/490,581 is a division of application No. 16/681,472, filed on Nov. 12, 2019, abandoned.
Application 16/681,472 is a continuation of application No. 15/460,396, filed on Mar. 16, 2017, abandoned.
Claims priority of provisional application 62/308,944, filed on Mar. 16, 2016.
Claims priority of application No. 1604458 (GB), filed on Mar. 16, 2016.
Prior Publication US 2024/0123044 A1, Apr. 18, 2024
Int. Cl. C07K 7/06 (2006.01); A61K 35/17 (2015.01); A61K 39/00 (2006.01); C07K 7/08 (2006.01); C07K 14/47 (2006.01); C07K 14/705 (2006.01); C07K 14/74 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C12N 5/0783 (2010.01); C12N 15/115 (2010.01); C12Q 1/6886 (2018.01)
CPC A61K 39/0011 (2013.01) [C07K 7/06 (2013.01); C07K 7/08 (2013.01); C07K 14/4748 (2013.01); C07K 14/705 (2013.01); C07K 14/70503 (2013.01); C07K 16/2803 (2013.01); C07K 16/2833 (2013.01); C07K 16/30 (2013.01); C12N 5/0638 (2013.01); C12N 15/115 (2013.01); C12Q 1/6886 (2013.01); A61K 2039/5158 (2013.01); A61K 2039/572 (2013.01); A61K 2039/80 (2018.08); C07K 2317/32 (2013.01); C07K 2319/40 (2013.01); C12N 2310/16 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01)] 20 Claims
 
1. A method of treating a patient who has hepatocellular cancer, comprising administering to said patient a population of activated T cells that kill cancer cells that present on the surface a peptide consisting of the amino acid sequence of KVLEHVVRV (SEQ ID NO: 1) wherein the activated T cells bind the peptide in a complex with an MHC class I molecule on the surface of the cancer cells.